Latest News
Veranex Acquires IMMR to Enhance Global Preclinical Studies
Wednesday 13 October 2021

North Carolina, US-based MedTech-focussed commercialisation service provider Veranex has acquired France-based preclinical science organisation acquisition IMMR, to enhance Veranex's services for preclinical studies worldwide, the company said.

Terms of the transaction were not disclosed.

Formed in June 2021 with global growth investor Summit Partners, Veranex provides the global medical technology industry with comprehensive and integrated solutions and services that accelerate the product life cycle to help improve the lives of patients everywhere.

As a result of this acquisition, Veranex gains state-of-the-art, FDA-inspected and AAALAC-accredited facilities and extensive in-house expertise, enhancing Veranex's services for preclinical studies worldwide.

For this transaction, financial advisors were Clearwater International and Cain Brothers, a division of KeyBanc Capital Markets, and Gide Loyrette Nouel, an international law firm located in Paris, served as legal counsel.
Details
Date Published: 13/10/2021

Options